| Stock | Price | 52 Week Range | Marketcap | EPS | Dividend Yield | Chart (24H) | Sector | Employees | Last Updated |
|---|---|---|---|---|---|---|---|---|---|
| $146.52 | 5.53B | 2.26 | 0.27% | Industrials | 10,000 | 1 minute ago | |||
| $112.88 | 81.89B | 7.80 | 4.17% | Financial Services | 53,597 | 56 seconds ago | |||
| $96.58 | 8.38B | 3.95 | 4.67% | Real Estate | 304 | 2 minutes ago | |||
| $119.14 | 147.83B | 5.04 | 2.68% | Healthcare | 17,600 | 3 seconds ago | |||
| $77.87 | 15.08B | 6.99 | 3.60% | Communication Services | 74,900 | 9 seconds ago | |||
 Pfizer, Inc. PFE | $25.41 | 144.44B | 1.89 | 6.79% | Healthcare | 81,000 | 1 second ago |
Last week’s market volatility left many questioning if Wednesday’s high-impact key reversal day (KRD) was the end of the bull run. However, the lack of follow-through suggests that the potential for gains later in the year remains high. As the market’s volatility continues, institutional investors face a pivotal choice: dive into bargain hunting or exit to the sidelines. The early trend this holiday-shortened week leans towards the former, giving astute investors a ripe opportunity to capitalize on undervalued stocks.
In an overbought market, focusing on stocks with intrinsic value is crucial. Our picks for June not only show growth potential but also offer dividends or unique features enhancing their attractiveness. Here are the top six stocks that should be on your radar this month.
Editor's Note: Analysis and insight for this article were originally sourced sourced from our friends at InvestorPlace
Top Stock to Buy #1 – Advanced Energy Industries (AEIS)
Breakout Signals 24% Upside Potential
Advanced Energy Industries (NASDAQ: AEIS) specializes in power conversion products, transforming power into various usable forms critical for semiconductor, solar panel, flat panel display, and data storage manufacturing. With expected earnings of $1.01 in 2013, $1.60 in 2014, and $1.82 in 2015 as per S&P estimates, AEIS is positioning itself for significant growth.
From a technical perspective, AEIS broke from a triple-top in December, catapulting from $15 to a high of $20 by early March. This was followed by a “V” consolidation pattern, signaling steady accumulation. A break above $20 is expected to trigger a rally towards $24, making AEIS an excellent buy at its current market price.
Click to Enlarge
Analyst Ratings and Forecasts:
| Metric | Value |
|---|---|
| Consensus Rating | Overweight |
| Average Price Target | $114.50 |
| Potential Gain | 24.1% |
| Number of Ratings | 7 |
Summary of Analysts’ Outlook:
Analysts have a positive outlook on Advanced Energy Industries, with a consensus rating of Overweight. The average price target of $114.50 suggests a potential gain of 24.1% from the current stock price. This indicates that analysts believe the stock has room for growth and is a good investment opportunity.
Top Stock to Buy #2 – Bank of Montreal (BMO)
A Heavyweight Stronghold for Stability & Growth
Bank of Montreal (NYSE: BMO), the fourth largest bank in Canada and eighth in North America, represents stability and consistent returns. Despite flat earnings for fiscal year 2013, projections for FY 2014 show an uptick to $6.42 per share, with a median price target of $67. Its dividend yield stands impressively at 4.8%.
BMO’s stock has recently been retreating, yet found steadfast support at its 200-day moving average, flashing a MACD buy signal. This suggests a near-term recovery is on the horizon. The target price for BMO is pegged at $68, hinting at an annual return potential of over 15%. For investors seeking stable yet growth-oriented assets, BMO is a prime candidate.
Click to Enlarge
Analyst Ratings and Forecasts:
| Metric | Value |
|---|---|
| Consensus Rating | Overweight (Buy) |
| Average Price Target | CAD 134.15 |
| Potential Gain | 14.1% |
| Number of Ratings | 12 |
Summary of Analysts’ Outlook:
Analysts have a positive outlook on Bank of Montreal, with a consensus rating of Overweight (Buy). The average price target suggests a potential gain of 14.1% from the current price. Most analysts expect BMO to continue benefiting from its diversified business mix, strong capital position, and improving credit quality.
Top Stock to Buy #3 – Federal Realty Investment Trust (FRT)
Prime Retail Assets Offering Strong Gains
Federal Realty Investment Trust (NYSE: FRT) manages premium retail properties in high-demand areas of the Northeast, Mid-Atlantic, and California. Its earnings growth has been steady, with a solid dividend yield of 2.6% and a 12-month target price of $128, as noted by S&P.
The stock took a dip from a triple-top at $118 but reversed course on a Collins-Bollinger Reversal (CBR) buy signal at just above $110. This pullback presents an advantageous entry point, allowing investors to buy into a high-quality REIT poised to deliver an annual return of more than 16%.
Click to Enlarge
Analyst Ratings and Forecasts:
| Metric | Value |
|---|---|
| Consensus Rating | Overweight |
| Average Price Target | $134.13 |
| Potential Gain | 14.1% |
| Number of Ratings | 13 |
Summary of Analysts’ Outlook:
Analysts have a positive outlook on Federal Realty Investment Trust, with a consensus rating of Overweight. The average price target of $134.13 suggests a potential gain of 14.1% from the current price. This indicates that analysts believe the stock has upside potential and is a good investment opportunity.
Top Stock to Buy #4 – Gilead Sciences (GILD)
New HIV Treatments Setting Up Big Wins
Gilead Sciences (NASDAQ: GILD) remains a dominant force in the biopharmaceutical industry, particularly in HIV and Hepatitis C treatments. Despite recent setbacks, such as the FDA’s rejection of two HIV candidate drugs, the European Commission’s approval of a single-tablet regimen for HIV-1 has rejuvenated investor confidence.
The stock has appreciated by 50% since our initial buy recommendation, and while previous holders may want to take profits, Gilead’s new HIV treatments could push the stock to a target of $65. For those seeking robust biopharma investments, GILD remains a top pick.
Click to Enlarge
Analyst Ratings and Forecasts:
| Metric | Value |
|---|---|
| Consensus Rating | Overweight (Buy) |
| Average Price Target | $73.44 |
| Potential Gain | 15.1% |
| Number of Ratings | 22 |
Summary of Analysts’ Outlook:
Analysts are generally bullish on Gilead Sciences, with a consensus rating of Overweight (Buy). The average price target of $73.44 suggests a potential gain of 15.1% from the current price. The company’s diverse portfolio of HIV, oncology, and inflammation treatments, as well as its strong cash flow generation, are seen as positives by analysts. However, some analysts have expressed concerns about the company’s dependence on its HIV franchise and the potential impact of patent expirations on its revenue growth.
Top Stock to Buy #5 – Omnicom Group (OMC)
Breakout Pattern Signals Buy Opportunity
Omnicom Group (NYSE: OMC) commands a leading position in the advertising industry, owning giants like DDB, BBDO, and TBWA networks. Its global reach and diversified revenue streams make it an industry bellwether. The company has a history of steady earnings, with projections extending this trend into the future.
OMC recently displayed a bullish breakout from a “double-top” pattern, supported by a CBR buy signal on high volume. The stock is slated to hit a trading objective of $73, making it a compelling buy amidst recovering ad spending.
Click to Enlarge
Analyst Ratings and Forecasts:
| Metric | Value |
|---|---|
| Consensus Rating | Hold |
| Average Price Target | $64.15 |
| Potential Gain | 12.1% |
| Number of Ratings | 13 |
Summary of Analysts’ Outlook:
Analysts have a mixed outlook on Omnicom Group Inc., with a consensus rating of Hold. The average price target of $64.15 implies a potential gain of 12.1% from the current price. While some analysts believe the company’s diversified portfolio and strong financial performance will drive growth, others are concerned about the impact of industry trends and competition on its advertising and marketing businesses.
Top Stock to Buy #6 – Pfizer (PFE)
Pharmaceutical Titan Set for 24% Profits!
Pfizer (NYSE: PFE) continues to justify its title as the world’s largest pharmaceutical company, regularly delivering earnings gains and dividend increases. The current dividend yield stands at 3.3%. Among its strategic moves, Pfizer plans to spin off its majority interest in Zoetis (NYSE: ZTS), allowing it to sharpen its focus on core business areas.
Strategically, PFE has been in a bullish trend since January 2012, breaking its resistance line on high volume and recently confirming support with a CBR buy signal at $28.50 and a new MACD buy signal. The 12-month target is set at $35, paving the way for a total return of 24%. Pfizer’s position in a diversified investment strategy is well warranted.
Click to Enlarge
Analyst Ratings and Forecasts:
| Metric | Value |
|---|---|
| Consensus Rating | Overweight (Buy) |
| Average Price Target | $44.45 |
| Potential Gain | 24.1% |
| Number of Ratings | 20 |
Summary of Analysts’ Outlook:
Analysts have a positive outlook on Pfizer, with a consensus rating of Overweight (Buy). The average price target of $44.45 suggests a potential gain of 24.1% from the current price. This indicates that analysts believe the stock has room for growth and is a good investment opportunity.